#18 00 100 OO GENELUX 100 Redefining Immuno-Oncology 088 OO 00 (80880 088389 Corporate Presentation | October 2023 0#2Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections, about Genelux Corporation ("Genelux," the "Company," "we," "us" or "our") that are based on the beliefs and assumptions of our management team, and on information currently available to such management team. These forward-looking statements include, but are not limited to, statements concerning: Olvi-Vec's potential utility and our plans and expectations for Olvi-Vec across various designs and indications; our expectations regarding the field of oncolytic viral immunotherapy; Olvi-Vec's potential to provide utility across multiple tumor types, and our expectations regarding our Phase 3 trial; our clinical trial strategy and design; our expectations regarding (i) the timing of our Phase 2 and Phase 3 clinical trials and (ii) our intellectual property rights under the Newsoara license agreement; our planned investments to meet worldwide clinical trial demand and facilitate our U.S. commercial launch; the commercial market opportunity for Olvi-Vec in the United States; our various commercial strategies for self-launching Olvi-Vec for ovarian cancer in the United States, including expected milestones related to clinical trials and commercial partnerships and collaborations; and our expectations regarding our cash operating runway. These forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control. All statements, other than statements of historical fact, contained in this presentation, including statements regarding future events, future financial performance, business strategy and plans, and objectives of ours for future operations, are forward-looking statements. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, and in our other filings with the SEC, which may cause our actual results, levels of activity, performance or achievements of and those of our industry to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on any forward-looking statement. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will" or "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all. Except as required by law, Genelux does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. Trade names, trademarks and service marks of other companies appearing in this presentation are the property of their respective owners. Solely for convenience, the trademarks and tradenames referred to in this presentation appear without the Ⓡ and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames. This presentation discusses a product candidate that is under clinical study and which has not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of this product candidate for the use for which it is being studied.#3Highlights 24600 GENELUX Olvi-Vec: De-risked late-stage Clinical Program Ongoing pivotal trial in late-stage Ovarian Cancer, SCLC and planned Phase 2 trial Adjuvant Maintenance NSCLC CHOICETM Platform; Broad and Diverse Discovery Engine Library with over 500 novel vaccinia strains and 110+ transgenes Validating Strategic Partnerships Newsoara Biopharma (Greater China rights) initiated a Phase 1b/2 clinical trial with Olvi-Vec in small-cell lung cancer and ELIAS Animal Health (global rights) is preparing a canine efficacy study with V-VET1 Focused Commercial Strategy US launch in Ovarian Cancer initially; strategic partnerships for ex-US rights Estimated Billion Dollar Plus Annual Market Opportunity in the U.S. Potential beyond this in numerous clinical settings 3#4The Most Advanced Non-local Delivery Oncolytic Immunotherapy Olvi-Vec: Engineered to selectively target and eliminate tumor cells while inducing a robust patient-specific immune response ■ Physician-preferred Routes of Delivery Regional and systemic administration to preferentially locate, colonize and destroy tumor cells In Ovarian Cancer trials, catheter placement is prior to chemotherapy, with removal 2 days after initial placement. IV therapy currently being used in small cell lung cancer Phase 1 trial. GENELUX Antitumor Effect and Well Tolerated Strong data in Phase 1b/2 study in platinum-resistant/refractory ovarian cancer (PRROC) No Maximum Tolerated Dose (MTD) observed+ Potential utility in multiple cancers (demonstrated in 20 pre-clinical tumor models), including metastatic disease Rey Ideal Backbone of Combination Therapy Turns tumors "hot" by localized inflammation and induction of the influx of tumor infiltrating lymphocytes (TILs) Positively modulates anti-tumor pathways in tumor microenvironment 4#5Diversified Designs and Indications Exploit Competitive Advantages Olvi-Vec Regional Route Systemic Route V2ACT Immunotherapy Systemic Route V-VET1 Systemic Route GENELUX Human Health Ovarian Cancer (platinum-resistant/refractory) Non-Small Cell Lung Cancer (Adjuvant Maintenance) Small Cell Lung Cancer (recurrent) Ovarian Cancer (recurrent) Non-Small Cell Lung Cancer (relapsed/recurrent) Pancreatic Cancer Animal Health Hematologic and solid tumors Design Olvi-Vec (i.pe) + Chemotherapy Olvi-Vec (IV) + Chemotherapy Olvi-Vec (IV) + Chemotherapy Olvi-Vec (IV) + Chemotherapy Olvi-Vec (IV) + Chemotherapy Olvi-Vec (IV) + Adoptive Cell Therapy V-VET1 (IV) +/- standard of care Preclinical Phase 2 Regulatory Submission Ph1b/2 enrolling Ph1b/2 Regulatory Submission Planned Preclinical Regulatory Submission Phase 1 Ph3 OnPrime/GOG-3076 Study Actively Enrolling Safety Preparing Phase 1 Phase 2 Preliminary Efficacy Phase 3 Phase 2 Phase 3 Pivotal Efficacy Collaborators GOG (Cooperative Group) FOUNDATION" Transforming the standard of care NEWSOARA 恒翼生物医药 (Greater China) VACT THERAPEUTICS (Worldwide Rights Ex-Greater China) ELIAS ANIMAL HEALTH (Worldwide) 5#6Selective Replication In Tumors Unleashes Immune System Against Cancer Key Takeaways Olvi-Vec is a robust immune modulator that utilizes a triple mode of action to mount a personalized attack against cancer cells throughout the body ● ● Kills cancer cells directly Enhances (neo) antigen presentation and stimulates a tumor- specific immune response Converts tumor microenvironment from immunosuppressive (cold state) to immunoreactive (hot state) GENELUX ● ● Olvi-Vec viral infection Oncolysis and release of tumor (neo)antigens 'Cold' tumor before Olvi-Vec No or relatively low number of immune effector cells Relatively high number of immune suppressor cells ● Innate Immune Activation Increase Type I IFNs Increase DAMPS / PAMPS ● Adaptive Immune Activation APCS present (neo)antigens T-cell activation & cytotoxicity Anti-tumor immune memory 'Hot' tumor following Olvi-Vec immunotherapy Increase of proinflammatory cytokines/chemokines Influx of CD8+ effector T cells M2 to M1 transition of tumor-associated macrophages Decrease of immune suppression Changes of tumor gene expression profile Immunogenic tumor cell death Reverse platinum-resistance and synergy with other therapies Vascular collapse PAMPS - Pathogen-associated Molecular Patterns DAMPS-Damage-associated Molecular Patterns 6#7Olvi-Vec-Primed Immunochemotherapy: Overcoming Drug Resistance GENELUX Pro-therapeutic gene expression Positive regulation of T-cell activating and trafficking Expression profiles correlated to better prognosis in cancer patients Promotion of sensitization/ response to chemotherapy Olvi-Vec-Induced Hot Tumor ABSENCE OF EFFECTOR T CELLS FIBROBLAST GSH 932932 cystine cysteine High GSH cystine Platinum resistant IFNY cystine cisplatin 0.0 000 CANCER PRESENCE OF EFFECTOR T CELLS APR --00 cysteine GG XXXX Low GSH GSH Platinum sensitive GOTS 78000 anscription- 93 GOTS Chemotherapy synergy Immunogenic cell death Depletion of suppressor cells Increase susceptibility to cytotoxic T-lymphocytes 7#8Over $4 Billion in Transactions in Active Oncolytic Space CG ONCOLOGY With its recent IPO, Genelux joined the public markets as a Phase 3 company A maturing field with Amgen launching Imlygic in 2014 and Phase 3 companies (CG Oncology, Replimune, GNLX) working to validate its power and potential GENELUX Emerging Late-Stage Modality AMGEN Acquired BioVex ($1b) 2011 AMGEN FDA approved IMLYGICTM 2015 Pfizer Collaboration with Ill Bristol Myers Squibb Western Oncolytics License Agreement with PsiOxus ($936m) 2016 Boehringer Ingelheim Acquired ViraTherapeutics ($245m) Celgene AstraZeneca License Agreement with Omnis Pharmaceuticals Participated in Oncorus' $57m Series A 2017 abbvie Collaboration with Turnstone Biologics 2018 GENELUX Janssen Acquired Benevir ($140m) REGENERON Collaboration with Vyriad Replimune® Replimune completed a $225 million offering as well as $200M in non-dilutive debt financing Replimune® $100m IPO MERCK Acquired Viralytics ($394m) CG Oncology raises aggregate $225 million in Series E and crossover financing for clinical-stage uro-onc pipeline 2019 Takeda Collaboration/ License Agreement with Turnstone Biologics ($120m) Genelux enters the public markets raising $68.5M in the first half of 2023 AstraZeneca Collaboration/ License Agreement with Transgene astellas Collaboration/ License Agreement with KaliVir ($634m) 2020 KISSEI Collaboration/ License Agreement with CG Oncology ($140m) Daiichi-Sankyo Approval of Teserpaturev 2021 ONCOLOGY $120m Series E GENELUX $171.5m License agreement with Newsoara 2022 Roche Collaboration with Replimune GENELUX IPO 2023 Replimune® CG ONCOLOGY $225m Secondary $105m Crossover Round 8#9Competitive Advantages of Olvi-Vec as an Oncolytic Virus Key Takeaways Olvi-Vec Key Advantages: Broad spectrum of activity Tumor selectivity ● ● ● ● ● ● Strong lytic activity / spread Strong immune activator Engineering capability Multiple routes of delivery Nonhuman pathogen Stable DNA virus Cytoplasmic, no genomic integration GENELUX Key Players and Assets GENELUX Olvi-Vec AMGEN Herpes Replimune Herpes Herpes CG ONCOLOGY Daiichi-Sankyo Adenovirus NCOLYTICS Reovirus BIOTECH INC Oncolytic Virus Space Olvi-Vec Key Advantages Target & Treat Metastatic Disease Systemic Delivery and redosing Robust Immune Activation Profile Target & Treat Tumors of Various Size IV dosing is the physician preferred administration technique, and our IV data has the potential to enable physician preferred administration vs. local-delivery-only assets 9#10Creating a New Paradigm Of Oncolytic Virus Drug Development GENELUX Our Advantage GENELUX Systemic Dosing and Redosing Target & Treat Metastatic Diseases 7 completed clinical trials ~150 patients AMGEN T-VEC (approved) in melanoma gains first clinical and regulatory validation of an oncolytic virus Robust Immune Activation Profile Broad spectrum of accessible tumor types Replimune® RP1 (registration directed trials) in skin cancer BCG ONCOLOGY CG0070 (Phase 3) in patients with non- muscle invasive bladder cancer unresponsive to BCG Olvi-Vec Our New Generation Olvi-Vec has the potential to redefine the oncolytic virus space and provide utility across multiple tumor types by enabling physician- preferred administration techniques and setting new benchmarks in efficacy and safety, as shown in multiple clinical trials. Genelux looks to its Phase 3 trial to potentially bring a best-in-class therapy to those patients in need. 1st Gen Viruses Commercial/Late-stage 1st Generation viruses confirm modality's potential, but all are limited to local delivery and scope of addressable cancers 10#11Phase 1b: Anti-tumor Activity as Monotherapy Leading into Combination Key Clinical Takeaways mPFS of 6.1 months (median 4 prior lines; 95%CI: 2.2-NA) for the six patients in Cohort 1 virus monotherapy - the dose used in Ph2- SOC-AURELIA regimen (1-2 prior lines; mPFS: 6.7 mos) ELAHARE (1-3 prior lines; mPFS: 5.62 mos Cohort 2/3 dosing done exponentially higher with no MTD reached. GENELUX Lo Pos Olvi-Vec Monotherapy Patient Background & Study Treatment Heavily pre-treated PRROC patients with documented progressive disease Cohort I received a Single cycle of intraperitoneal delivery on 2 consecutive days; total dose: 6x10⁹ pfu, same dose as Phil/III ● Tolerability: No Dose Limiting Toxicity (DLT) No Maximum Tolerated Dose (MTD) No Grade 4 Adverse Events (AE) ● Antitumor activity: Clinical Benefit Rate: 73% (8/11) 4/11 patients had >2x PFS relative to immediate prior chemotherapy Translational Evidence: Activation of tumor-specific T cell response detected in blood Documented immune activation in tumor microenvironment with significant influx of TILS Favorable immune-related genetic signatures ● ● Manyam et al., Gynecologic Oncology 163 (2021) 481 - 489 11#12Completed Phase 2 Tested Olvi-Vec Immunochemotherapy Olvi-Vec Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer Key Inclusion Criteria High-grade serous, endometrioid or clear-cell ovarian cancer which includes: platinum-resistant or PRROC with at least two prior lines of therapy ECOG Performance status is at 0 or 1 GENELUX Design Olvi-Vec via intraperitoneal infusion in multiple doses, after systemic chemotherapy administered with or without bevacizumab Interventional Single Group Assignment n=27 Endpoints Primary: Median progression-free survival (mPFS); Objective Response Rate (ORR) by RECIST 1.1 and by tumor biomarker Cancer Antigen-125. Secondary: Median overall survival (MOS) TM JAMA Oncology Data Presentations 1. 2020 Digital Annual Meeting of International Gynecologic Cancer Society UN Results of the VIRO-15 Phase 2 Trial were published in JAMA Oncology (Link) Oral Plenary Session 2. JAMA Oncology Selected for Journal podcast series interview OnPrime Phase 3 Trial Ongoing Pivotal Phase 3 for the treatment of PRROC patients, using the same Experimental Arm treatment regimen 12#13Clinically-Meaningful Responses in Heavily Pretreated Patients Key Clinical Takeaways Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC ● ● All patients had documented progressive disease at enrollment Overall response rate in 27 patients was 54% with 7.6- month median duration of response Historical PFS in this patient population is ~4 mos GENELUX Overall Response Rate (ORR) & Progression-Free Survival (PFS)* ORR by RECIST 1.1** ORR by CA-125 Median PFS All patients (n=27) (95% CI) Platinum-resistant (n=14) (95% CI) Platinum-refractory (n=13) (95% CI) 54% (13%24) (33-74) 55% (6/11) (26-84) 54% (7/13) (27-81) Duration Response 7.6 mos (3.7 - 9.6) 7.6 mos (3.7 - NA) 8.0 mos (3.7 - NA) 85% (22/26) (65 - 96) 85% (11/13) (55-98) 85% (11/13) (55-98) 11.0 mos (6.7 - 13.0) 10.0 mos (6.4 - NA) 11.4 mos (4.3 -13.2) Median OS 15.7 mos (12.3 - 23.8) 18.5 mos (11.323.8) 14.7 mos (10.8 -33.6) *Baseline for ORR & PFS evaluation is the timepoint immediately prior to starting post-Olvi- Vec carboplatin doublet +/- bevacizumab to allow direct comparison to historical data or patients' own previous line of chemotherapy **Eligible for evaluation: with at least 1 measurable target lesion at baseline; including 2 patients without post-chemo scan after virotherapy, and therefore are assigned to the 'inevaluable for response' category per RECIST1.1 "Including 3 unconfirmed; 2 in resistant and 1 in refractory groups 13#14Demonstrated Deep and Durable Tumor Shrinkage Tumor Shrinkage Key Clinical Takeaways Refractory patients performed as well as resistant patients Tumor Shrinkage Overall, 86% of PRROC patients showed tumor reduction, with 91% of Platinum-refractory patients showing tumor reduction ● Four patients had 100% reduction target lesions (two with confirmed CR), including two platinum-refractory patients Duration of Response (DOR) DOR of 7.6 Months in all platinum- ● Resistant patients DOR of 8.0 Months in platinum- refractory patients GENELUX Change of target lesion size (% change of SLD) Best change of target lesions from baseline (%) 100 80 60 40 20 60 40 20 -20 -40 -20 -40 -30% partial response -60 -80 -100 -60 -80 15A-18 -100 15B-09 158-19 15A-19 15A-27 E-POS 120 platinum-resistant platinum-refractory 15B-18 15A-06 15A-30 180 SA-2 158-01 15A-29 240 Duration of Response Baseline tumor burden as Sum of Longest Diameter of target lesions (mm) 15A-05 Time (days) 300 15A-37 158-17 360 15A-22 15A-16 SA-0 PD OR (CR or PR) SD 420 15A-25 480 158-15 15A-31 SA-3 540 -30% partial response 14#15Olvi-Vec-Primed Immunochemotherapy Overcomes "Refractoriness" Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines (mos) PFS 16.0 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 ● ● ● Overall Survival: 23.2 Months Failed 10 Prior Lines ● 8.7 GENELUX 15B-01: Stage IIIB papillary serous ECOG: 0 BRCA negative PD-L1 negative R# 1: taxol + carbo ÏÏÏ 3.7 4.0 3.0 1.4 R#2: Doxil + carbo 12.0 R#3: Avastin R#4: cisplatin + Gemzar 10.9 Regimens R#5: Tamoxifen + Provera + etoposide R#7: etoposide 5.4 R#8: topotecan R#6: Tamoxifen + Megace + Femara 1.4 R#9: carbo 9.3 15.5 R#10: Rubraca R#11: Olvi-Vec + C/Bev (mos) PFS 12 10 8 Overall Survival: 12.3 Months Failed 6 Prior Lines 6 4 2 0 ● 8.1 ● ● ● 15B-15: Stage IIIB high- grade serous ECOG: 0 R#1: carbo + taxol BRCA negative PD-L1 negative 6.1 5 R#2: olaparib + cediranib R# 3: Gemzar + IMGN853 3 R#4: Doxil+Bev R#5: topotecan 2 Regimens 2 10.3 R#6: cisplatin + Gemzar Olvi-Vec-primed C/Bev (mos) PFS 14.0 Overall Survival: 15.7 Months Failed 7 Prior Lines 12.0 ● 10.0 8.0 6.0 4.0 2.0 0.0 ● ● 15B-17: Stage IIIC high- grade serous ECOG: 1 BRCA negative 6.0 6.5 ÏÏÏ 3.0 3.0 R#1: Carbo+ Gemzar/Doxil R#2: Niraparib R#3: Cytoxan + Bev R#4: Taxol + Bev 6.0 R#5: Pembrolizumab Regimens 1.8 R#6: SC003 0.3 11.5 R#7: Carbo + Doxil R#8: Olvi-Vec-primed C/Bev 15#16Durable Benefit of Overall Survival via Clinically-Validated Endpoint Historical Data 21.1 MOS 12.0 MOS 9.8 MOS Not reported [Bookman et al., Gynecol Oncol. 2017;146(1):58-63] VIRO-15 Key Clinical Takeaways 20% long-term survivors consistent with commercially successful immunotherapies Historical data in 4th line and beyond shows a median overall survival of only 9.8 months On a median 5th line of treatment, VIRO-15 Ph2 patients achieved a mos of 15.7 mos 4 of 6 long-term survivors were platinum-refractory at enrollment GENELUX OS, proportion 1.0 0.8 0.6 0.4 0.2 0.0 0 10 Number at risk 27 21 20 10 2nd line 3rd line 4th line 5th line 5th line (med) 30 Month Durable Benefit: 20% long-term survivors (median follow-up time: 47.0 mos) 6 40 15.7 MOS 4 50 (95% CI, 17.8-24.4) (95% CI, 10.4-14.6) (95% CI, 7.1-12.25) 2 (95%, 12.323.8) 60 2 16#17"Allcomers" Approach May Reset Life Clock of Heavily Pre-treated Patients While clinical remissions are obtainable, a majority of patients will relapse. Genelux looks to take an all-comers approach Key Trial Takeaways Olvi-Vec addresses a broad and underserved pool of patients ● Olvi-Vec trial inclusion criteria allows patients regardless of (i) tumor biomarkers, (ii) platinum refractory tumors, or (iii) number of prior lines of treatment (i.e., no cap) Olvi-Vec Phase 2 results approach results in less pre-treated platinum- sensitive patients GENELUX GENELUX 100% 80% 60% 40% 20% 0% Study AURELIA¹ B-GEMOX² FORWARD IF VB-1114 JAVELIN-200 TOPACIOS VIRO-15 OCEANS GENELUX RECIST1.1 # or prior lines 54% ≤2 prior lines 1-2 (21%), 3-4 (63%), ≥ 5 (16%) Median 3 prior lines ≤ 3 prior lines <3 prior lines ≤ 4 prior lines Median 4 prior lines GENELUX 85% Regimen Platinum-resistant / refractory patients CA-125 (3) (4) Platinum-sensitive patients Chemo + Avastin (i.e., CT+Bev) Oxali + Gem + Avastin Mirvetuximab soravtansine + pembrolizumab (median/high FRa group) VB-111 + paclitaxel Avelumab + PLD Niraparib + pembrolizumab Olvi-Vec / Chemo ± Avastin No prior chemo in recurrent setting References (1) Pujade-Lauraine et al., J Clin Oncol 2014;32:1302-1308. (2) Ikeda et al., Int J Gynecol Cancer 2013;23:355-360. Footnote: As the data presented is based on a cross-trial comparison and not a head-to-head clinical trial, such comparisons may not be reliable due to differences in study protocols, conditions and patient populations. Accordingly, cross-trial comparisons may not be reliable predictors of the relative efficacy or other characteristics of our candidates compared to others presented. Carbo + Gem + Avastin GENELUX 77% Matulonis et al., ESMO 2018. Arend et al., Gynecol Oncol. 2020;157:578-584. PFS-6-month (5) (6) Konstantinopoulos et al., J Clin Oncol 2018;36(S15)106. Aghajanian et al., Gynecol Oncol. 2015;139(1):10-16. 17#18● Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the tumor microenvironment Key Inclusion Criteria High-grade serous, endometrioid, or clear-cell ovarian cancer. Platinum-resistant or -refractory disease Received prior bevacizumab (or biosimilar) treatment. Received a minimum of 3 prior lines of systemic therapy with no maximal limit. Performance status ECOG is at 0 or 1, and life expectancy of at least 6 months GENELUX Multi-center, randomized open-label n=186 Experimental Arm Olvi-Vec and Platinum-doublet + Bevacizumab, followed by maintenance therapy Active Comparator Arm Platinum-doublet + Bevacizumab, followed by maintenance therapy Enrollment expected to be completed as early as mid-2024, with 11-month follow-up Primary Endpoint Progression-Free Survival A platinum resensitizing agent is a long-standing desirable and highly demanded mechanism of action of Gyn-Oncs, their so-call "Holy Grail". * Key Secondary Endpoints 1. Treatment-emergent AES 2. Duration of Response (DOR) 3. Overall Response Rate (ORR) 4. Overall Survival (OS) *Journal of Investigative Medicine High Impact Case Reports, Volume 6: 1-3, 2018 DOI: 10.1177/2324709618760080 Journals.sagepub.com/home/hic 18#19Systemic administration demonstrated dose-dependent OS benefit Key Trial Takeaways Demonstrated feasibility and clinical benefit of multiple IV cycles ● ● Median 5 prior lines of therapy Regimen: various dosing levels and schedules (typically over 4-6 months) Well tolerated: no-MTD reached with one DLT Clinical Benefit: statistically significant overall survival (OS) benefit in primary and metastatic lung diseases GENELUX otal Cumulative Dose (TCD; in pfu) 1.00E+11 1.00E+10 1.00E+09 1.00E+08 1.00E+07 1.00E+06 1.00E+05 Dose escalation study . 3.0*** 10 Group A Group B 20 Patient Dose Escalation Phase 1b Monotherapy Study in Solid Tumors Progressed from Last Prior Therapy 30 40 Probability 1.0 0.8 0.6 0.4 0.2 0.0 A B 0 Number at risk 11 11 10 3 7 20 1 72 2 OS..mos. 30 0 1 40 0 1 Group A: (n=11; lower-dose group with TCD ranging from 2x105 pfu - 2×10⁹ pfu) Group B: (n=11; higher-dose group with TCD ranging from 3×10⁹ pfu - 3×10¹⁰ pfu) Group B B 50 0 0 Groups lower vs higher TCD: median Overall Survival at 4.6 months (95% CI: 1.3 -11.0) vs 16.8 months (95% CI: 5.9-NA); p = 0.026; a statistically significant clinical benefit favoring the higher dose group. 1.00E+11 1.00E+10 1.00E+09 1.00E+08 1.00E+07 1.00E+0 1.00E+05 Dose escalation study 14 " too O Group A 10 20 Patient Group B 06 30 1.0 40 0.8 0.4 02 0.0 A B 0 Number at risk 5 сл сл 5 5 2 5 10 OS mos. 51 52 The ROYAL MARSDEN NHS Foundation Trust ICR 2 Group A: (n=5; lowest-dose group with TCD ranging from 2×105 pfu - 1×106 pfu) Group B: (n=5; highest-dose group with TCD ranging from 1×10¹0 pfu - 3×10¹0 pfu) 15 0 3 The Institute of UNIVERSITY OF SURREY Groups lowest vs highest TCD: median Overall Survival at 4.6 months (95% CI: 2.7 - NA) vs 20.9 months (95% CI: 16.8 - NA); p = 0.002; a statistically significant clinical benefit favoring the highest dose group. Group 19 20 0 1 A#20Systemic Administration + Chemo Generated Encouraging Data Key Trial Takeaways Anti-tumor effect of IV Immunochemotherapy ● ● High and Condensed Dosing (single cycle: bolus infusion on 5 consecutive days) Well tolerated: No DLT or MTD reached Monotherapy: Anti-tumor effects Combination therapy: Virus treatment revitalized tumors to subsequent chemotherapy with prolonged PFS and OS GENELUX Recurrent metastatic cervical cancer with lung mets Case Report (Pt #21A-06) Received 5 consecutive daily i.v. doses Cancer Advent Health Institute Expanded Access Program Transient adverse reactions: fever, nausea, bone pain (Hx arthritis) Stable disease with no tumor size increase 55 53 51 49 47 45 43 41 39 37 35 SLD of nontarget lesions (mm) PD at SD at baseline Wk 24 11/2017 20/2018 /1/2018 10/2018 Chemotherapy after disease progression Partial Response PFS: 70+ Weeks OS: 53.4 Months High-grade pancreatic cancer with lung & liver mets Case Report (Pt.#21A-04) Received 5 consecutive daily i.v. doses Transient adverse reactions: fever, nausea 59% drop of CA19.9 tumor biomarker and Objective Response per RECIST, with PFS of 18 weeks Best change (%) of target lesion sizes from baseline by RECIST Wk 7 0 -5 -10 -15 -20 -25 -30 -35 -40 Partial response Chemotherapy after disease progression 83% drop of CA 19.9 Partial Response by RECIST PFS: 31 wks 20#21Genelux has Partnered with Newsoara BioPharma Co., Ltd GENELUX GENELUX NEWSOARA 恒翼生物医药 Benny Li, PhD Founder and Chief Executive Officer 20+ yrs. global and China local pharma Former VP, GM of Takeda China Development Center and SVP, Executive GM of R&D at Hansoh Pharmaceuticals Former Head of Clinical Development & Medical Affairs in Asia at Alcon/Novartis $850 Million Valuation 7 Pipelines. 12 Indications NEWSOARA HIGHLIGHTS Top 10 Blue-chip Biotech Investors 5 Phase IIb/I|| 2 Phase II 2023 IPO Planned Newsoara has paid $11M to date and GNLX is eligible for additional development, regulatory and sales milestone payments and up to mid-double-digit percentages royalties on net sales 21#22Validating Industry Collaboration with Newsoara BioPharma Co., Ltd Key Takeaways • Newsoara will fund the US-based Genelux Phase 2 trial in NSCLC • Newsoara has development and commercialization rights in Greater China • Interim readout for one or more systemic administration trials expected as early as mid-2024 GENELUX Sponsor G NEWSCARA Trial Sites US China Systemic Program: Clinical Trials Indication Adjuvant Maintenance NSCLC Recurrent SCLC Recurrent OC Recurrent NSCLC Clinical Stage Phase II Phase I/II Phase I/II Phase I/II Patients (est.) ~138 -150 ~150 ~ 150 Randomization 2:1 Single Arm 2:1 2:1 Status Regulatory Submission Enrolling Regulatory Submission Planned Genelux will have worldwide commercial rights (excluding Greater China) to all data generated from clinical trials of Olvi-Vec in China. 22#23V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical VACT V2ACT Therapeutics is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. established to develop and test V2ACT. Key Trial Takeaways V2ACT Immunotherapy, combines an oncolytic immunotherapy and adoptive cell therapy ● Induces an acute inflammatory response in the tumor and converts tumor microenvironment from immunosuppressive to immunostimulatory; Anticipated to enhance effect of neoantigen specific effector T cells GENELUX Vaccination increases the numbers of neoantigen-specific T cells in the body and Olvi-Vec kills cancer cells and potentiates T cells by increasing cancer tissue receptivity to adoptively transferred neoantigen-specific effector T cells. Technology Patients Dosed Regulatory TVI Adoptive Cell Therapy ~ 130 Fast Track Designation / FDA Grant - glioblastoma Olvi-Vec Oncolytic Immunotherapy ~ 150 Phase 3 enrolling - ovarian Novel 10 modality: United States Patent No. 11,633,442, issued in April 2023 23#24Estimated Billion Dollar Plus annual Olvi-Vec Commercial Opportunity (US) Ovarian Cancer Non-Small Cell Lung Cancer GENELUX Additional revenue drivers: Re-treatment ➤ Front-Line therapy ➤ Additional Indications, i.e.: Small Cell Lung Cancer Pancreatic Cancer 1. Polaris Market Research 2. NIH Ovarian Cancer Fact Sheet =100,000 patients Ovarian Cancer Market¹ ~$1.8B in 2022, expected CAGR growth ~23.5% iii 70-80% will relapse ~236,511 women in the US currently 2 Drivers of Market Penetration The Phase 3 population is a broad category of patients with significant unmet medical need, including those excluded from other therapies or trials. 24#25Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch Large-Scale cGMP Manufacturing Process to Optimize Production Key Takeaways ● ● ● Established and equipped an independent, Company- controlled 7,500+ Sq. Ft. manufacturing facility in San Diego to secure material for pivotal studies and potential commercial supply CGMP material manufactured and released for the ongoing Phase 3 Trial and Newsoara's trials Planned investment to augment internal development capabilities as well as continually improve proprietary manufacturing processes Genelux aims to meet worldwide clinical trial demand and U.S. commercial launch GENELUX Headquarters Westlake Village, CA, USA Research and Development San Diego, CA, USA So De SCIENCE SAN DIEGO ENCE CENTER CENTER fear Science Starts Manufacturing Facility San Diego, CA, USA Facilities and Operations: Based in Southern California 25#26Commercial Strategy Leverage partnership with GOG Foundation ● Partnerships GENELUX Preeminent US-based cooperative group in Gynecologic Oncology Composed of leading KOLS in the field Partners in the OnPrime/GOG-3076 Phase 3 registration trial Self Launch Olvi-Vec for Ovarian Cancer in the US ● ● 屈 Self-Manufacturing Large-Scale cGMP Manufacturing Control of Production Schedule Attractive COGS Ability to scale up modular process ● ● Patients Population without Standard of Care PRROC patients lack effective SoC therapies Limited number of Gyn- Oncs enabling specialty sales team Label expansion starting with IV administration in 2L ovarian (Ph2 planned) Compelling Value Proposition for Payors ● Reimbursement ● Significant unmet medical need No SOC Combination with generic/biosimilars 26#27Choice Platform Library: 500+ Vectors with 110+ Transgenes Therapeutic Genes Immune Modularity Therapeutic Antibodies GENELUX Engineered and selected clonal isolated (non-GMO) viral strains identified from in vitro and in vivo selection criteria Virus-encoded transgenes Cell Growth & Differentiation Regulators Metastasis Suppressor Genes Cell Matrix Degradative Genes Immune Regulators Superantigens Cytokines/Chemokines Single-chain Antibodies Hormones ✓ In vitro & in vivo tested: GLP Tox ready Immune Modularity Molecules IL-6/SIL-6R O O IL-24 Cell Growth & Differentiation Regulators OBMP-4 Cell Matrix-Degradative Genes OhMMP9 Clonal Isolated Strains (non-GMO) o V-VETI (LIVP6.1.1) o Cop15.1.1 O LIVP1.1.1 O LIVP5.1.1 Single-Chain Antibodies o Anti-VEGF Anti-DLL4 Anti-CTLA4 o Anti-PD-1 o Anti-FAP o Anti-PD-L1 o Anti-avẞ3- integrin 27#28Intellectual Property: Market Exclusivity & Freedom to Operate GENELUX 0-0-0-0 + Patent Portfolio: 33 issued patents; 7 pending Olvi-Vec covered by Composition of Matter (2031) and Manufacturing (2038) Olvi-Vec: Worldwide operating freedom; No third-party royalties due Long Duration of Regulatory / Marketing Exclusivity Strong IP & Regulatory Designations 28#29Accomplished Leadership Team Executive Team Thomas Zindrick, JD Chief Executive Officer AMGEN aeromics DNX ONIAMMACEUT CALS Tony Yu, PhD SVP, ClinDev Operations & R&D UC San Diego MOORES CANCER CENTER Lourie Zak Chief Financial Officer GENELUX AMGEN Guter SONIFI PBS Center Joseph Cappello, PhD Chief Technical Officer U UNIVERSITY B BRAUN OF UTAH SHARING EXPERTISE THE Paul Scigalla, MD, PhD Chief Medical Officer Pfizer NUEVOLUTION PRC Caroline Jewett Head, Quality AMGEN & Sean Ryder, JD General Counsel H HELSINN mesoblast Ralph Smalling Head, Regulatory Affairs AMGEN UC San Diego MOORES CANCER CENTER Board of Directors THOMAS ZINDRICK, JD Chairman of the Board JAMES L. TYREE, MBA Lead Independent Director MARY MIRABELLI, MBA Director JOHN THOMAS, MBA, PhD Director Qian Zhang, MD, PhD VP, Clinical Sciences Doug Samuelson VP, Finance SECONDSIGHT Medacta AdvaVet USA AMGEN aeromics + DNX MAUT DALI Pfizer ll Bristol Myers Squibb Hewlett Packard Enterprise La Sierra UNIVERSITY JOHN SMITHER, CPA (Inactive) AMGEN KYTHERA EY Director Abbott hfma healthcare financial management association HCA+ Healthcare ADRA BIOPHARMACEUTICALS Cathy Gust VP, Program Mgmt AMGEN 29#30Genelux Has Executed on Multiple Milestones and is Positioned for the Future Executed Milestones Executed on go public strategy and follow on with $60M raised Initiation of Phase 3 Trial in PRROC Phase 2 results published in JAMA Oncology Collaboration and License agreement with Newsoara Initiation of Phase 1b/2 trial in recurrent SCLC (China) Issuance of V2ACT US Patent GENELUX Initiate Phase 2 trial in (Adjuvant Maintenance) NSCLC Enter additional regional development & commercial partnership(s) and platform collaborations Initiate Phase 1/2 trial in recurrent ovarian cancer (IV route) Initiate Ph1b/2 trial of V2ACT 30#31Expected Operating Runway into 1Q 2026 GENELUX 1) 2) Capitalization Summary Stock Symbol GNLX Share Price (¹) $28.89 Shares Outstanding 25.98M Market Capitalization (¹) $750M Cash & Equivalents (2) $28.40M PIPE Commitments Due $ 25M** Insider Ownership FULLY DILUTED 29.4% At market close on July 18th, 2023. As of July 18th, 2023. Analyst Coverage Bruce Jackson M.S., MBA The Benchmark Company Kemp Dolliver CFA Brookline Capital Markets Jason McCarthy, Ph.D. Maxim Group 2023 Financing Events January IPO: $15M May Private Placement: $33M June Private Placement: $18M *Reconciliation of Cap Table and Balance Sheet: -All Preferred Series (1400 A-K investors) to Common -$32M (debt and accrued dividends) to Common Includes $25M that two investors will, and are contractually obligated to, fund no later than November 15, 2023. 31#32Highlights 24600 GENELUX Olvi-Vec: De-risked late-stage Clinical Program Ongoing pivotal trial in late-stage Ovarian Cancer, SCLC and planned Phase 2 trial Adjuvant Maintenance NSCLC CHOICETM Platform; Broad and Diverse Discovery Engine Library with over 500 novel vaccinia strains and 110+ transgenes Validating Strategic Partnerships Newsoara Biopharma (Greater China rights) initiated a Phase 1b/2 clinical trial with Olvi-Vec in small-cell lung cancer and ELIAS Animal Health (global rights) is preparing a canine efficacy study with V-VET1 Focused Commercial Strategy US launch in Ovarian Cancer initially; strategic partnerships for ex-US rights Estimated Billion Dollar Plus Annual Market Opportunity in the U.S. Potential beyond this in numerous clinical settings 32#338 00 100 100 (80880 GENELUX Redefining Immuno-Oncology Corporate Presentation | October 2023 Appendix 0#34Accomplished Clinical Advisory Board Medical Director, Gynecologic Oncology, AdventHealth Cancer Institute Chief Medical Officer, Vanium Group Co-Director, Gynecologic Oncology, Hoag Memorial Hospital Presbyterian Deputy Director of the University of Cincinnati Cancer Institute Professor and Division Director, Ohio State University Comprehensive Cancer Center Forsythe & Bear, LLC GENELUX Robert Holloway, MD CHAIRMAN Robert Coleman, MD Member Albert A. Mendivil, MD Member Thomas J. Herzog, MD Chief Executive Officer David M. O'Malley, MD Chief Medical Officer Alan Forsythe, PhD Chief Financial Officer Dr. Holloway is the principal investigator for VIRO-15 and has served on several committees of the Society of Gynecologic Oncology (SGO), including its Board of Directors. Dr. Coleman currently serves on the Board of Directors of Gynecologic Oncology Group and is co-Director of GOG-Partners. In addition, he is immediate Past-President of the International Gynecologic Cancer Society. Dr. Mendivil, site principal investigator for VIRO-15, serves as Co-Director of Gyn- Onc and Complex Pelvic Surgery, Hoag Hospital. He has been the principal investigator or site sub-investigator on 20+ clinical trials. Dr. Herzog is President-Elect of the GOG Foundation. He has served on the leadership board or council of SGO, the Foundation for Women's Cancer, and ACOG. Dr. O'Malley is the clinical trial advisor/lead for ovarian cancer within GOG Partners, a committee member for the NCI Gynecologic Cancer Steering Committee's Ovarian Task Force and the NRG Oncology. Dr. Forsythe has had a distinguished career in pharmaceutical drug development. As Vice President of Corporate Biomedical Information at Amgen, Alan led the Biostatistics, Epidemiology and HOER depts. 34#35Olvi-Vec Demonstrates Monotherapy Oncolysis and Immune Activation Key Takeaways Olvi-Vec monotherapy shows decreased tumor cells and increase immune activation Olvi-Vec treatment was able to dramatically decrease or eliminate tumor cells in multiple patient samples The Activation of Immunosurveillance by Olvi-Vec after 2 doses was seen in multiple cavities as monotherapy GENELUX Olvi-Vec Treatment on Days 3 & 4 baseline Clusters of tumor cells Limited immune cells Oncolysis Day 5 ܀ (Pt.#15A-01) Day 10 Drastic reduced tumor cells Large increase of immune cells Immune activation (Pt.#15A-11) Elimination of Cancer Cells after Increased Lymphocyte Infiltration in different cavities peritoneal fluid pleural fluid Prior to 1st dose W2D12 (VIRO-15: monotherapy) W2D17 W2D9 Tumor cell clusters present W2D15 Robust lymphocyte count increase W2D17 Tumor cell clusters absent 35#36CD8+ T-cells: Infiltrating Lymphocytes are Prognostic for Response/Survival Induced tration of CD8+ cells into Tumors Shift of CD8+ cells into Endogenous TILS (intra- tumoral and stromal) are very low in ovarian cancer epithelial tissue Pre-Olvi-Vec GENELUX Post-Olvi-Vec (prior to subsequent chemotherapy) Baseline Screening CD4 CD4 Inside Post Outside Tumor Treatment R 8 15 4 100μm 10 5 100μm -200 200- 8 100 -200 Pt# 15A-16 CD4+ CD8 Pt# 15A-16 -100 CD8 -100 HALO™ Infiltration Histogram CD8+ densities around interface 42 1:00 Distance from interface [um] 100μm 100 Distance from Interface [um] CD8+ 100μm- HALO™ Infiltration Histogram CD8+ densities around interface 705 146 14 200 Inside Tumor 200 CD4 CD4 Outside Tumor CD8+ permm² CD8+per mm² 40 30 10 100μm CD4+ 100μm -200 150- 0- -200 Pt# 15A-18 Pt# -100 CD8 I CD8 1:00 Distance from Interface [um] -100 Pt# 15A-18 HALO™ Infiltration Histogram CD8+ densities around interface 126 45 100μm 100 Distance from Interface [um] CD8+ 100μm HALO™ Infiltration Histogram CD8+ densities around interface 494 109 200 Inside Tumor 200 CD4 CD4 Outside Tumor 4 100μm CD4+ 04 30 -200 4100μm 01 -200 15A-23 -100 CD8 O CD8 Pt# 15A-23 HALO™ Infiltration Histogram CD8+ densities around interface 107 69 1:00 Distance from Interface [um] 100μm 1:00 CD8+ Distance from Interface [um] 100μm HALO™ Infiltration Histogram CD8+ densities pround interface: 135 28 200 200 36#37Long-lasting, Tumor-specific T cell response corresponds to tumor reduction (VIRO-15: monotherapy) Confirms tumor-antigen presentation & immune activation/memory Key Takeaways Off-the-Shelf Personalized Medicine: Single Agent generates Individualized Results • Olvi-Vec induces favorable & long-lasting Tumor-specific T-cell Response (TSTCR) by ELISPOT analysis in patient in heavily treated patient w/ 9 prior regimens of chemo; no Tumor-specific T-cell response at baseline ● Documented OR from Olvi- Vec treatment after failure of last chemotherapy GENELUX Case Report (Pt #15A-05) Heavily pre-treated: 9 prior regimens of chemo+Avastin; no pre-existing tumor-specific T-cells Post treatment: Consequential amount (~3%) of all activatable T cells at Week 30 are tumor-specific T-cells Last Chemotherapy: Pemetrexed 3/30-5/18/2016 300 280 260 240 220 200 180 Partial response (confirmed on Week 24 & 36; durable) 160 140 120 Progressive disease (PD) (CT scans on 6/30/2016 & 8/30/2016) GL-ONC1 Tx Stable disease @ Week 48 (-27% compared to baseline) SLD (mm) -24 IFN-gamma secreting cells / 100,000 PBMCs 10000 pemetrexed 1000 100 50 40 30 20 10 0 No pre-existing tumor-specific T-cell response Neg. Control (Ovalbumin) Baseline SLD of target lesions over time No TSTCR + 90% PD 0 Vaccinia Virus Lysate 价 Olvi-Vec Administration Week 6 Wks 18 Tumor lysate Activation of tumor-specific T-cell response (TSTCR) Week 30 Positive Control (PMA/ION) 1 Confirmed TSTCR - 34% PR 36 37#38Olvi-Vec: Ideal Backbone for Combination Therapy Converts Tumor Microenvironment to Inflammatory "Hot Spot" Induction of acute inflammatory cytokines GENELUX (Th1-type related) VIRO-15 Study Endogenous PD-L1 expression in ovarian tumor is low, hence limiting target by Fold-change from Baseline anti-PD-1/PD-L1 therapy Rodriguez-Freixinos et al. J Clin Oncol 36, 2018 (suppl; abstr 5595) 6 N Up Regulates Immunomodulatory Target Proteins, such as PD-L1 Percentage of cases Baseline W1D5 W2D10 W3D17 80% 100% 1 60% PIL-6 CRP SAA TNF-α 40% PIL-15 TARC IP-10 20% 0% n=24 (25%) (46%) PD-L1 expression <1% <20% [20%-50%] >50% NCT01443260/TUE Study MEDCOM RESAMPLED-Vedute komp Baseline MEDCOM RESAMPLED-Verlustbehate kompeniet Baseline Massive inflammatory response after cycle 1 of virus treatment PD-L1: VIRO-15 Study Post treatment (20d) Strong PD-L1 staining at the tumor-stromal interface 38